Journal article icon

Journal article

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Abstract:

Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population.

Methods PANORAMIC was a UK-based, national, mul...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/S0140-6736(22)02597-1

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Primary Care Health Sciences
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Primary Care Health Sciences
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Primary Care Health Sciences
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Research group:
Oxford Respiratory Trials Unit
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Primary Care Health Sciences
Role:
Author

Contributors

More from this funder
Name:
UK National Institute for Health and Care Research
Publisher:
Elsevier
Journal:
The Lancet More from this journal
Volume:
401
Issue:
10373
Pages:
281–293
Publication date:
2022-12-22
Acceptance date:
2022-11-30
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
Language:
English
Keywords:
Pubs id:
1317031
Local pid:
pubs:1317031
Deposit date:
2022-12-23

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP